Shumilov, Evgenii; Hoffknecht, Petra; Koch, Raphael; Peceny, Rudolf; Voigt, Steffen; Schmidt, Nicole; Peeck, Micha; Bacher, Ulrike; Scheithauer, Simone; Trümper, Lorenz; Lenz, Georg; Kerkhoff, Andrea; Bleckmann, Annalen (2021). Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. Cancers, 13(12) MDPI AG 10.3390/cancers13122917
|
Text
Diagnostic__Clinical_and_Post-SARS-CoV-2_Scenarios_in_Cancer.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
Oncologists face challenges in the management of SARS-CoV-2 infections and post-SARS-CoV-2 cancer treatment. We analyzed diagnostic, clinical and post-SARS-CoV-2 scenarios in patients from three German cancer centers with RT-PCR confirmed SARS-CoV-2 infection. Sixty-three patients with SARS-CoV-2 and hematologic or solid neoplasms were included. Thirty patients were initially asymptomatic, 10 of whom developed COVID-19 symptoms subsequently. Altogether 20 (32%) patients were asymptomatic, 18 (29%) had mild, 12 (19%) severe and 13 (20%) critical courses. Lymphocytopenia increased risk of severe/critical COVID-19 three-fold (p = 0.015). Asymptomatic course was not associated with age, remission status, therapies or co-morbidities. Secondary bacterial infection accompanied more than one third of critical COVID-19 cases. Treatment was delayed post-SARS-CoV-2 in 46 patients, 9 of whom developed progressive disease (PD). Cancer therapy was modified in 8 SARS-CoV-2 survivors because of deteriorating performance or PD. At the last follow-up, 17 patients had died from COVID-19 (n = 8) or PD (n = 9) giving an estimated 73% four-month overall survival rate. SARS-CoV-2 infection has a heterogenous course in cancer patients. Lymphocytopenia carries a significant risk of severe/critical COVID-19. SARS-CoV-2 disruption of therapy is as serious as SARS-CoV-2 infection itself. Careful surveillance will allow early restart of the anti-cancer treatment.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Bacher, Vera Ulrike |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2072-6694 |
Publisher: |
MDPI AG |
Language: |
English |
Submitter: |
Pierrette Durand Lüthi |
Date Deposited: |
12 Jul 2021 12:26 |
Last Modified: |
04 May 2024 05:19 |
Publisher DOI: |
10.3390/cancers13122917 |
PubMed ID: |
34208007 |
Uncontrolled Keywords: |
COVID-19 SARS-CoV-2 SARS-CoV-2 scenarios cancer patients |
BORIS DOI: |
10.48350/157424 |
URI: |
https://boris.unibe.ch/id/eprint/157424 |
Actions (login required)
 |
Edit item |